Share this
Digg
Del.icio.us
Reddit
StumbleUpon
Slashdot
Netscape
Furl
Yahoo
Blogmarks
Technorati
Newsvine
Googlize this
Blinklist
Facebook
Wikio
Export PDF
Print
E-mail
Vita Birzniece, Udo Meinhardt, James Gibney, Gudmundur Johannsson, Robert C. Baxter, Markus J. Seibel, and Ken K. Y. Ho*
Garvan Institute of Medical Research and Department of Endocrinology (V.B., U.M., J.G., G.J., K.K.Y.H.), St. Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales (K.K.Y.H.), Sydney, NSW 2052, Australia; Kolling Institute of Medical Research (R.C.B.), The University of Sydney, Royal North Shore Hospital, Sydney, NSW 2065 Australia; and ANZAC Research Institute (M.J.S.), The University of Sydney at Concord, NSW 2139, Australia
* To whom correspondence should be addressed. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
Context: The metabolic action of GH is attenuated by estrogens administered via the oral route. Selective estrogen receptor modulators lower IGF-I to a lesser degree than 17β-estradiol in GH-deficient women, and their effect on fat and protein metabolism is unknown.
Objective: The aim of the study was to compare the modulatory effects of 17β-estradiol and raloxifene, a selective estrogen receptor modulator, on the metabolic action of GH. Design: We conducted an open-label, two-group, randomized, two-period crossover study.
Patients and Intervention: Ten hypopituitary women received GH therapy alone (0.5 mg/d) and GH plus 17β-estradiol (E2; 2 mg/d). Eleven hypopituitary women received GH therapy alone and GH plus raloxifene (R; 60 mg/d). The treatment duration was 1 month, with a 4-wk washout period.
Main Outcome Measures: IGF-I, IGFBP-3, resting energy expenditure, and fat oxidation were quantified by indirect calorimetry. We measured whole body leucine turnover from which leucine rate of appearance and leucine incorporation into protein were estimated.
Results: GH significantly stimulated all outcome measures. During GH treatment, addition of R significantly reduced mean IGF-I but not IGFBP-3, whereas E2 reduced both IGF-I and IGFBP-3 levels. Cotreatment with R but not E2 significantly attenuated the stimulatory effects of GH on fat oxidation. There was a strong trend (P = 0.08) toward a greater reduction in leucine incorporation into protein after R compared to E2 cotreatment.
Conclusions: The modulatory effects of E2 and R at therapeutic doses on GH action are different. R during GH therapy exerts a greater inhibitory effect on lipid oxidation and protein anabolism compared to E2
From http://jcem.endojournals.org/cgi/content/abstract/jc.2009-2743v1